ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

ClinicalTrials.gov ID: NCT06168409

Public ClinicalTrials.gov record NCT06168409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

Study identification

NCT ID
NCT06168409
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
218 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2024
Primary completion
Aug 16, 2025
Completion
Aug 16, 2025
Last update posted
Feb 5, 2026

2024 – 2025

United States locations

U.S. sites
16
U.S. states
8
U.S. cities
16
Facility City State ZIP Site status
Research Site Surprise Arizona 85374
Research Site Hollywood Florida 33024
Research Site Lake Worth Florida 33467
Research Site Port Charlotte Florida 33952
Research Site Fort Wayne Indiana 46804
Research Site Lexington Kentucky 40503
Research Site The Bronx New York 10455
Research Site Greenville North Carolina 27834
Research Site Jacksonville North Carolina 28546
Research Site Kinston North Carolina 28504
Research Site New Bern North Carolina 28562
Research Site Wilmington North Carolina 28401
Research Site Langhorne Pennsylvania 19047
Research Site Brownsville Texas 78526
Research Site Corpus Christi Texas 78404
Research Site Lampasas Texas 76550

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06168409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06168409 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →